Resverlogix Corp RVXCF
Trading Information
- Previous Close Price
- $0.05
- Day Range
- $0.05–0.05
- 52-Week Range
- $0.04–0.10
- Bid/Ask
- $0.04 / $0.07
- Shares Outstanding
- 344.29M
- Market Cap
- $15.92M
- Volume/Avg
- 700 / 16,938
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 17
- Website
- https://www.resverlogix.com
Valuation
Metric | RVXCF |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | RVXCF |
|---|---|
Quick Ratio | 0.03 |
Current Ratio | 0.04 |
Interest Coverage | −1.21 |
Quick Ratio
RVXCF
Profitability
Metric | RVXCF |
|---|---|
Return on Assets (Normalized) | −121.84% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RVXCF
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|<q<Wh?! | LOCK|yKDJ | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|^r#GkBq | LOCK|&v>>d | $98B | |||
| Moderna Inc MRNA | LOCK|B$#?V#V | LOCK|SRB | $80B | |||
| argenx SE ADR ARGX | LOCK|?GL#jkw | LOCK|^# | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|SSW?mcP | LOCK|$k | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|%@V>Wc@g | LOCK|xcp% | $31B | |||
| Incyte Corp INCY | LOCK|Hwpp?<> | LOCK|#V# | $24B | |||
| BioNTech SE ADR BNTX | LOCK|nKJ#<#> | LOCK|kg | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|R^&%?<> | LOCK|^P@Q | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|g?^%&l | LOCK|g! | $16B |